X-Linked Lymphoproliferative Syndrome 2
1 drug in active X-Linked Lymphoproliferative Syndrome 2 trials · Updated 18 Nov 2026
Furthest along
1 in Phase 2
Next Phase 3 result
None yet
Drugs
1
In active trials, any stage
Trials
1 active
No sub-diseases
Drugs1
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Multi-specific immunoglobulin |
Phase 2 | — | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Also tested for | NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | ||||
| Open drug page | |||||
How trials write it1
The conditions trials list that we place on X-Linked Lymphoproliferative Syndrome 2 itself, with their active trials
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations 1
About
- Summary
- 1 drug is in active X-Linked Lymphoproliferative Syndrome 2 trials. Updated 18 Nov 2026.
- Registry term
- Lymphoproliferative Syndrome, X-Linked, 2
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026